Advanced search
1 file | 520.85 KB Add to list

REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer

Author
Organization
Abstract
Purpose: REQUITE aimed to establish a resource for multi-national validation of models and biomarkers that predict risk of late toxicity following radiotherapy. The purpose of this article is to provide summary descriptive data. Methods: An international, prospective cohort study recruited cancer patients in 26 hospitals in eight countries between April 2014 and March 2017. Target recruitment was 5300 patients. Eligible patients had breast, prostate or lung cancer and planned potentially curable radiotherapy. Radiotherapy was prescribed according to local regimens, but centres used standardised data collection forms. Pre-treatment blood samples were collected. Patients were followed for a minimum of 12 (lung) or 24 (breast/prostate) months and summary descriptive statistics were generated. Results: The study recruited 2069 breast (99% of target), 1808 prostate (86%) and 561 lung (51%) cancer patients. The centralised, accessible database includes: physician-(47,025 forms) and patient-(54,901) reported outcomes; 11,563 breast photos; 17,107 DICOMs and 12,684 DVHs. Imputed genotype data are available for 4223 patients with European ancestry (1948 breast, 1728 prostate, 547 lung). Radiation-induced lymphocyte apoptosis (RILA) assay data are available for 1319 patients. DNA (n = 4409) and PAXgene tubes (n = 3039) are stored in the centralised biobank. Example prevalences of 2-year (1-year for lung) grade >= 2 CTCAE toxicities are 13% atrophy (breast), 3% rectal bleeding (prostate) and 27% dyspnoea (lung). Conclusion: The comprehensive centralised database and linked biobank is a valuable resource for the radiotherapy community for validating predictive models and biomarkers. Patient summary: Up to half of cancer patients undergo radiation therapy and irradiation of surrounding healthy tissue is unavoidable. Damage to healthy tissue can affect short-and long-term quality-of-life. Not all patients are equally sensitive to radiation "damage" but it is not possible at the moment to identify those who are. REQUITE was established with the aim of trying to understand more about how we could predict radiation sensitivity. The purpose of this paper is to provide an overview and summary of the data and material available. In the REQUITE study 4400 breast, prostate and lung cancer patients filled out questionnaires and donated blood. A large amount of data was collected in the same way. With all these data and samples a database and biobank were created that showed it is possible to collect this kind of information in a standardised way across countries. In the future, our database and linked biobank will be a resource for research and validation of clinical predictors and models of radiation sensitivity. REQUITE will also enable a better understanding of how many people suffer with radiotherapy toxicity.
Keywords
Oncology, Radiology Nuclear Medicine and imaging, Hematology

Downloads

  • Requite.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 520.85 KB

Citation

Please use this url to cite or link to this publication:

MLA
Seibold, Petra, et al. “REQUITE: A Prospective Multicentre Cohort Study of Patients Undergoing Radiotherapy for Breast, Lung or Prostate Cancer.” Radiotherapy and Oncology, vol. 138, ELSEVIER IRELAND LTD, 2019, pp. 59–67.
APA
Seibold, P., Webb, A., Aguado-Barrera, M. E., Azria, D., Bourgier, C., Brengues, M., … Li, W. (2019). REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. Radiotherapy and Oncology, 138, 59–67.
Chicago author-date
Seibold, Petra, Adam Webb, Miguel E. Aguado-Barrera, David Azria, Celine Bourgier, Muriel Brengues, Erik Briers, et al. 2019. “REQUITE: A Prospective Multicentre Cohort Study of Patients Undergoing Radiotherapy for Breast, Lung or Prostate Cancer.” Radiotherapy and Oncology 138: 59–67.
Chicago author-date (all authors)
Seibold, Petra, Adam Webb, Miguel E. Aguado-Barrera, David Azria, Celine Bourgier, Muriel Brengues, Erik Briers, Renée Bultijnck, Patricia Calvo-Crespo, Ana Carballo, Ananya Choudhury, Alessandro Cicchetti, Johannes Claßen, Elena Delmastro, Alison M. Dunning, Rebecca M. Elliott, Laura Fachal, Marie-Pierre Farcy-Jacquet, Pietro Gabriele, Elisabetta Garibaldi, Antonio Gómez-Caamaño, Sara Gutiérrez-Enríquez, Daniel S. Higginson, Kerstie Johnson, Ramón Lobato-Busto, Meritxell Mollà, Anusha Müller, Debbie Payne, Paula Peleteiro, Giselle Post, Tiziana Rancati, Tim Rattay, Victoria Reyes, Barry S. Rosenstein, Dirk De Ruysscher, Maria Carmen De Santis, Jörg Schäfer, Thomas Schnabel, Elena Sperk, R. Paul Symonds, Hilary Stobart, Begoña Taboada-Valladares, Christopher J. Talbot, Riccardo Valdagni, Ana Vega, Liv Veldeman, Tim Ward, Christian Weißenberger, Catharine M.L. West, Jenny Chang-Claude, Yolande Lievens, Marc Van Eijkeren, Katrien Vandecasteele, Elhaseen Elhamin, Piet Ost, Valerie Fonteyne, Martijn Swimberghe, Pieter Deseyne, Wilfried De Neve, Fréderic Duprez, Marcus Mareel, Christel Monten, Annick Van Greveling, Tom Vercauteren, Leen Paelinck, Gilles Defraene, Rita Aerts, Soumia Arredouani, Maarten Lambrecht, Ben Vanneste, Roxana Draghici, Frank Giordano, Carsten Herskind, Marlon Veldwijk, Irmgard Helmbold, Ulrich Giesche, Petra Stegmaier, Christian Weiß, Thomas Blaschke, Burkhard Neu, Laura Lozza, Barbara Avuzzi, Sara Morlino, Claudia Sangalli, Marzia Franceschini, Belina Rodriguez-Lage, Juan Fernández-Tajes, Olivia Fuentes-Rios, Isabel Domínguez-Rios, Irene Fajardo-Paneque, Paloma Sosa-Fajardo, Laura Torrado-Moya, Mónica Ramos-Albiac, Alexandra Giraldo, Manolo Altabas, Bibiana Piqué-Leiva, David García-Relancio, Alejandro Seoane-Ramallo, Samuel Lavers, Simon Wright, Hannah Dobbelaere, Donna Appleton, Monika Kaushik, Frances Kenny, Hazem Khout, Jaroslaw Krupa, Kelly V. Lambert, Simon Pilgrim, Sheila Shokuhi, Kalliope Valassiadou, Luis Aznar-Garcia, Ion Boiangui, Kiran Kancherla, Christopher Kent, Kufre Sampson, Ahmed Osman, Thiagarajan Sridhar, Subramaniam Vasanthan, Corinne Faivre-Finn, Victoria Harrop, Manjusha Keni, Karen Foweraker, Abigail Pascoe, Claire Esler, Richard Stock, Sheryl Green, Ava Golchin, and William Li. 2019. “REQUITE: A Prospective Multicentre Cohort Study of Patients Undergoing Radiotherapy for Breast, Lung or Prostate Cancer.” Radiotherapy and Oncology 138: 59–67.
Vancouver
1.
Seibold P, Webb A, Aguado-Barrera ME, Azria D, Bourgier C, Brengues M, et al. REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. Radiotherapy and Oncology. 2019;138:59–67.
IEEE
[1]
P. Seibold et al., “REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer,” Radiotherapy and Oncology, vol. 138, pp. 59–67, 2019.
@article{8645532,
  abstract     = {Purpose: REQUITE aimed to establish a resource for multi-national validation of models and biomarkers that predict risk of late toxicity following radiotherapy. The purpose of this article is to provide summary descriptive data.

Methods: An international, prospective cohort study recruited cancer patients in 26 hospitals in eight countries between April 2014 and March 2017. Target recruitment was 5300 patients. Eligible patients had breast, prostate or lung cancer and planned potentially curable radiotherapy. Radiotherapy was prescribed according to local regimens, but centres used standardised data collection forms. Pre-treatment blood samples were collected. Patients were followed for a minimum of 12 (lung) or 24 (breast/prostate) months and summary descriptive statistics were generated.

Results: The study recruited 2069 breast (99% of target), 1808 prostate (86%) and 561 lung (51%) cancer patients. The centralised, accessible database includes: physician-(47,025 forms) and patient-(54,901) reported outcomes; 11,563 breast photos; 17,107 DICOMs and 12,684 DVHs. Imputed genotype data are available for 4223 patients with European ancestry (1948 breast, 1728 prostate, 547 lung). Radiation-induced lymphocyte apoptosis (RILA) assay data are available for 1319 patients. DNA (n = 4409) and PAXgene tubes (n = 3039) are stored in the centralised biobank. Example prevalences of 2-year (1-year for lung) grade >= 2 CTCAE toxicities are 13% atrophy (breast), 3% rectal bleeding (prostate) and 27% dyspnoea (lung).

Conclusion: The comprehensive centralised database and linked biobank is a valuable resource for the radiotherapy community for validating predictive models and biomarkers.

Patient summary: Up to half of cancer patients undergo radiation therapy and irradiation of surrounding healthy tissue is unavoidable. Damage to healthy tissue can affect short-and long-term quality-of-life. Not all patients are equally sensitive to radiation "damage" but it is not possible at the moment to identify those who are. REQUITE was established with the aim of trying to understand more about how we could predict radiation sensitivity. The purpose of this paper is to provide an overview and summary of the data and material available.

In the REQUITE study 4400 breast, prostate and lung cancer patients filled out questionnaires and donated blood. A large amount of data was collected in the same way. With all these data and samples a database and biobank were created that showed it is possible to collect this kind of information in a standardised way across countries.

In the future, our database and linked biobank will be a resource for research and validation of clinical predictors and models of radiation sensitivity. REQUITE will also enable a better understanding of how many people suffer with radiotherapy toxicity.},
  author       = {Seibold, Petra and Webb, Adam and Aguado-Barrera, Miguel E. and Azria, David and Bourgier, Celine and Brengues, Muriel and Briers, Erik and Bultijnck, Renée and Calvo-Crespo, Patricia and Carballo, Ana and Choudhury, Ananya and Cicchetti, Alessandro and Claßen, Johannes and Delmastro, Elena and Dunning, Alison M. and Elliott, Rebecca M. and Fachal, Laura and Farcy-Jacquet, Marie-Pierre and Gabriele, Pietro and Garibaldi, Elisabetta and Gómez-Caamaño, Antonio and Gutiérrez-Enríquez, Sara and Higginson, Daniel S. and Johnson, Kerstie and Lobato-Busto, Ramón and Mollà, Meritxell and Müller, Anusha and Payne, Debbie and Peleteiro, Paula and Post, Giselle and Rancati, Tiziana and Rattay, Tim and Reyes, Victoria and Rosenstein, Barry S. and De Ruysscher, Dirk and De Santis, Maria Carmen and Schäfer, Jörg and Schnabel, Thomas and Sperk, Elena and Symonds, R. Paul and Stobart, Hilary and Taboada-Valladares, Begoña and Talbot, Christopher J. and Valdagni, Riccardo and Vega, Ana and Veldeman, Liv and Ward, Tim and Weißenberger, Christian and West, Catharine M.L. and Chang-Claude, Jenny and Lievens, Yolande and Van Eijkeren, Marc and Vandecasteele, Katrien and Elhamin, Elhaseen and Ost, Piet and Fonteyne, Valerie and Swimberghe, Martijn and Deseyne, Pieter and De Neve, Wilfried and Duprez, Fréderic and Mareel, Marcus and Monten, Christel and Van Greveling, Annick and Vercauteren, Tom and Paelinck, Leen and Defraene, Gilles and Aerts, Rita and Arredouani, Soumia and Lambrecht, Maarten and Vanneste, Ben and Draghici, Roxana and Giordano, Frank and Herskind, Carsten and Veldwijk, Marlon and Helmbold, Irmgard and Giesche, Ulrich and Stegmaier, Petra and Weiß, Christian and Blaschke, Thomas and Neu, Burkhard and Lozza, Laura and Avuzzi, Barbara and Morlino, Sara and Sangalli, Claudia and Franceschini, Marzia and Rodriguez-Lage, Belina and Fernández-Tajes, Juan and Fuentes-Rios, Olivia and Domínguez-Rios, Isabel and Fajardo-Paneque, Irene and Sosa-Fajardo, Paloma and Torrado-Moya, Laura and Ramos-Albiac, Mónica and Giraldo, Alexandra and Altabas, Manolo and Piqué-Leiva, Bibiana and García-Relancio, David and Seoane-Ramallo, Alejandro and Lavers, Samuel and Wright, Simon and Dobbelaere, Hannah and Appleton, Donna and Kaushik, Monika and Kenny, Frances and Khout, Hazem and Krupa, Jaroslaw and Lambert, Kelly V. and Pilgrim, Simon and Shokuhi, Sheila and Valassiadou, Kalliope and Aznar-Garcia, Luis and Boiangui, Ion and Kancherla, Kiran and Kent, Christopher and Sampson, Kufre and Osman, Ahmed and Sridhar, Thiagarajan and Vasanthan, Subramaniam and Faivre-Finn, Corinne and Harrop, Victoria and Keni, Manjusha and Foweraker, Karen and Pascoe, Abigail and Esler, Claire and Stock, Richard and Green, Sheryl and Golchin, Ava and Li, William},
  issn         = {0167-8140},
  journal      = {Radiotherapy and Oncology},
  keywords     = {Oncology,Radiology Nuclear Medicine and imaging,Hematology},
  language     = {eng},
  pages        = {59--67},
  publisher    = {ELSEVIER IRELAND LTD},
  title        = {REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer},
  url          = {http://dx.doi.org/10.1016/j.radonc.2019.04.034},
  volume       = {138},
  year         = {2019},
}

Altmetric
View in Altmetric
Web of Science
Times cited: